FDA Strengthens Invokana, Farxiga Acute Kidney Injury Risk Warnings

(June 20, 2016, 9:38 AM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on June 14 said it has strengthened the existing warnings for the risk of acute kidney injury on the diabetes drugs Invokana (canagliflozin) and Farxiga (dapaglifozin)....

Related Sections